Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vasomotor Symptoms; Hot Flashes Clear all
Completed Phase 2 Interventional Results available

Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer

NCT03646162
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Veru-944, Placebo
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Glendale, Arizona • Los Angeles, California • San Bernardino, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Not applicable Interventional

Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women

NCT07408115
View directory record Official record
Conditions
Hot Flashes, Hot Flash, Hot Flushes, Menopause, Postmenopause, Hot Flushes and/or Sweats, Hot Flushes, Night Sweats, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms Associated With Menopause
Interventions
JDS-HF3.0
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Harrison, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally

NCT05071729
View directory record Official record
Conditions
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
Interventions
Elinzanetant (BAY3427080)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms

NCT01418209
View directory record Official record
Conditions
Hot Flashes, Menopause, Vasomotor Disturbance
Interventions
Low-dose 17-ß-estradiol with progesterone taper, Venlafaxine XR, Placebo
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
339 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • Chestnut Hill, Massachusetts • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women

NCT01080300
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended Release, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause

NCT05030584
View directory record Official record
Conditions
Vasomotor Symptoms Associated With Menopause, Hot Flashes
Interventions
Elinzanetant (BAY3427080), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
36
States / cities
Mobile, Alabama • Mesa, Arizona • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Phase 2 Interventional

A Clinical Trial to Study DR-2031 for the Treatment of Hot Flashes in Prostate Cancer Patients

NCT00196339
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cyproterone acetate 5, Placebo, Cyproterone acetate 15, Cyproterone acetate 25
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years and older · Male only
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
98
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 87 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause

NCT04003155
View directory record Official record
Conditions
Hot Flashes
Interventions
fezolinetant, placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
72
States / cities
Andalusia, Alabama • Birmingham, Alabama • Ensley, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Not applicable Interventional

Acupuncture in Menopause

NCT01276028
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
Acupuncture
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms

NCT02865538
View directory record Official record
Conditions
Post-menopausal Vasomotor Symptoms
Interventions
BAY3427080, Placebo (for BAY3427080)
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
DeLand, Florida • Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study of Stellate Ganglion Injection to Provide Relief From Hot Flushes

NCT00992914
View directory record Official record
Conditions
Hot Flashes, Menopause
Interventions
Sympathetic nerve block with 1% lidocaine 1-2 ml, Superficial subcutaneous injection
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mindfulness Based Stress Reduction for Hot Flashes

NCT00317304
View directory record Official record
Conditions
Hot Flashes, Stress
Interventions
Mindfulness-based stress reduction
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

NCT03291067
View directory record Official record
Conditions
Menopause Hot Flashes
Interventions
MT-8554 1mg, MT-8554 5mg, MT-8554 10mg, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
63
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jun 10, 2026, 2:24 AM EDT
Recruiting Phase 2 Interventional

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

NCT06957691
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent, Prostate Carcinoma, Prostate Neoplasm, Prostate Adenocarcinoma, Prostate Cancer With Bone Metastasis, Vasomotor Disturbance, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Vasomotor Symptoms; Hot Flashes, Androgen Deprivation Therapy, Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma, Androgen-deprivation Therapy, Hot Flashes, Hot Flushes, Hot Flushes and/or Sweats
Interventions
fezolinetant - reference formulation, Placebo
Drug
Lead sponsor
Shehzad Basaria, M.D.
Other
Eligibility
40 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

NCT04209543
View directory record Official record
Conditions
Vasomotor Symptoms, Menopausal Symptoms
Interventions
Estetrol, Placebo, Progesterone
Drug
Lead sponsor
Estetra
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
65
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

Low-dose Hormone Therapy for Relief of Vasomotor Symptoms

NCT00446199
View directory record Official record
Conditions
Vasomotor Symptoms, Hot Flashes
Interventions
0.5mg DRSP / 0.5mg E2 (BAY86-4891), 0.25mg DRSP / 0.5mg E2 (BAY86-4891), Estradiol (E2 0.3mg), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Jun 10, 2026, 2:24 AM EDT
Recruiting Phase 2 Interventional

Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer

NCT06972875
View directory record Official record
Conditions
Prostate CA, Androgen Deprivation Therapy
Interventions
Fezolinetant
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Not applicable Interventional Results available

Reproductive Health Survivorship Care Plan

NCT02667626
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Sexual Dysfunction, Fertility, Contraception
Interventions
Reproductive Health Survivorship Care Plan (SCPR), Control
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women

NCT01829919
View directory record Official record
Conditions
Postmenopausal Symptoms
Interventions
Brisdelle (paroxetine mesylate)
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
40 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Phase 2 Interventional

Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause

NCT00314964
View directory record Official record
Conditions
Hot Flashes
Interventions
PD-0299685
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
56
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2011 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Phase 2 Interventional

Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes

NCT00160342
View directory record Official record
Conditions
Hot Flushes, Menopause, Postmenopause
Interventions
Esterified Estrogens (EE) and Methyltestosterone (MT)
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
1,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
88
States / cities
Montgomery, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2008 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Phase 2 Interventional

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms

NCT05312567
View directory record Official record
Conditions
Vasomotor Symptoms, Menopause
Interventions
FP-101
Drug
Lead sponsor
Fervent Pharmaceuticals
Industry
Eligibility
46 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Lomita, California • Long Beach, California • West Covina, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MsFLASH-04: Pilot Trial: Telephone Behavioral Therapy for Menopause-related Sleep Disturbance

NCT01936441
View directory record Official record
Conditions
Hot Flashes, Menopause, Vasomotor Disturbance, Sleep
Interventions
Cognitive Behavioral Therapy-Insomnia (CBT-I), Menopause Education Control (MEC)
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Jun 10, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

NCT01101841
View directory record Official record
Conditions
Hot Flashes
Interventions
Brisdelle (paroxetine mesylate), Placebo capsules
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
40 Years and older · Female only
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
32
States / cities
Montgomery, Alabama • Chandler, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Jun 10, 2026, 2:24 AM EDT